As Parallele makes its presence felt, Affymetrix suffers another setback... In what seems like a cordial three way collaboration, Affymetrix (AFFX), Parallele BioScience and Cambridge University announced today that they will work together in one of the most informative genetic studies of type I diabetes ever planned. But one could wonder why the Cambridge scientists did not choose Affymetrix chips to read out SNPs, or why they did not go to Affymetrix’s subsidiary Perlegen to get the study underway? The reason is that Parallele’s technology is so far ahead of anything Affymetrix has to offer that it is a no-brainer. Back in April we stated that Parallele was going to eat Affymetrix’s lunch when it came to SNPs and that prediction is coming true.
